Dec. 15 Quick Takes: Mythic Raises $103M series B

A $103 million series B will help Mythic Therapeutics Inc. push its lead antibody-drug conjugate (ADC) through first-in-human studies in lung cancer and advance other programs generated using its FateControl technology. Co-founded by President and CEO Alex Nichols and CSO Brian Fiske in 2017, The Waltham, Mass.-based biotech is developing ADCs that aim to deliver a higher proportion of their payload to the target compared with other approaches to improve the therapy’s therapeutic index.

Viking Global Investors led the round with participation from fellow new investors Foresite Capital, Perceptive Advisors and Highside Capital. Existing investors Venrock, First Round Capital, OMX Ventures, LifeForce Capital and Refactor Capital also participated. Venrock’s Bryan Roberts First Round’s Josh Kopelman and Peter Hecht, CEO of Cyclerion Therapeutics Inc. (NASDAQ:CYCN) are on the company’s board with Nichols and Fiske...